Cervical Dystonia Treatment with Injections Supplemented by Transcranial Magnetic Stimulation: The D-TWIST Pilot Randomized Controlled Trial.

IF 3.4 4区医学 Q2 CLINICAL NEUROLOGY

Movement Disorders Clinical Practice Pub Date : 2026-10-11 DOI:10.1002/mdc3.70862

Jessica Frey, Aparna Wagle Shukla, Janine Lobo Lopes, Lauren Fanty, Manahil Wajid, Adolfo Ramirez-Zamora, Irene A Malaty, Jackson Cagle, Coralie de Hemptinne, David M Scarisbrick, Patrick Worhunsky, Jun Yu

{"title":"Cervical Dystonia Treatment with Injections Supplemented by Transcranial Magnetic Stimulation: The D-TWIST Pilot Randomized Controlled Trial.","authors":"Jessica Frey, Aparna Wagle Shukla, Janine Lobo Lopes, Lauren Fanty, Manahil Wajid, Adolfo Ramirez-Zamora, Irene A Malaty, Jackson Cagle, Coralie de Hemptinne, David M Scarisbrick, Patrick Worhunsky, Jun Yu","doi":"10.1002/mdc3.70862","DOIUrl":null,"url":null,"abstract":"Background: For some patients with cervical dystonia (CD), botulinum toxin (BoNT) injections last less than 12 weeks.Objectives: To determine if a novel, accelerated repetitive transcranial magnetic stimulation (rTMS) protocol is a safe and feasible adjunctive treatment with BoNT for CD.Methods: Patients with CD reporting BoNT benefit lasting ≤9 weeks were enrolled in a randomized double-blind, sham-controlled, crossover study. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), mood, cognitive, and gait measures were collected before, after, and 2-weeks following rTMS/SHAM.Results: In a homogenous subset of patients (N = 4/5), TWSTRS scores were lower 2-weeks following rTMS, but evidence of an effect was potentially limited by sample size. There was little evidence of rTMS effects on mood, cognition, or gait.Conclusions: Accelerated rTMS for CD was safe, feasible, and well-tolerated; larger randomized studies are needed to determine whether accelerated rTMS may be an effective treatment bridge for dystonia symptoms.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655560/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mdc3.70862","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: For some patients with cervical dystonia (CD), botulinum toxin (BoNT) injections last less than 12 weeks.

Objectives: To determine if a novel, accelerated repetitive transcranial magnetic stimulation (rTMS) protocol is a safe and feasible adjunctive treatment with BoNT for CD.

Methods: Patients with CD reporting BoNT benefit lasting ≤9 weeks were enrolled in a randomized double-blind, sham-controlled, crossover study. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), mood, cognitive, and gait measures were collected before, after, and 2-weeks following rTMS/SHAM.

Results: In a homogenous subset of patients (N = 4/5), TWSTRS scores were lower 2-weeks following rTMS, but evidence of an effect was potentially limited by sample size. There was little evidence of rTMS effects on mood, cognition, or gait.

Conclusions: Accelerated rTMS for CD was safe, feasible, and well-tolerated; larger randomized studies are needed to determine whether accelerated rTMS may be an effective treatment bridge for dystonia symptoms.

查看原文本刊更多论文

注射加经颅磁刺激治疗颈肌张力障碍：D-TWIST先导随机对照试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Movement Disorders Clinical Practice CLINICAL NEUROLOGY-

CiteScore

4.00

自引率

7.50%

发文量

218

期刊介绍： Movement Disorders Clinical Practice- is an online-only journal committed to publishing high quality peer reviewed articles related to clinical aspects of movement disorders which broadly include phenomenology (interesting case/case series/rarities), investigative (for e.g- genetics, imaging), translational (phenotype-genotype or other) and treatment aspects (clinical guidelines, diagnostic and treatment algorithms)